UNAIDS Commends Merck ATRIPLA Decision

... UNAIDS commends Merck's decision to register ATRIPLA indeveloping countries. The registration of ATRIPLA, a once-daily single tablet regimen fortreatment of HIV infection in adults, exemplifies the joint efforts of two research anddevelopment leaders, Merck Co. and Gilead Sciences to make essential medicines availableto those in need. [click link for full article] ...